Bulletin from the annual general meeting in Biovica

2020-08-27 17:10

The following resolutions were passed at the annual general meeting of Biovica AB (publ) on 27 August 2020 in Uppsala.

Adoption of the accounts for the financial year 2019/2020 and discharge from liability
The annual general meeting, AGM, resolved to adopt the income statement and balance sheet, as well as the consolidated income statement and consolidated balance sheet for the 2019/2020 financial year. The members of the board of directors and the CEO were discharged from liability for the financial year 2019/2020.

Allocation of profit or loss
The AGM resolved that no dividend shall be paid for the financial year 2019/2020 and that the results of the company shall be carried forward.

Renumeration to the board of directors and auditor
The AGM resolved that renumeration to the members of the board of directors shall be SEK 150,000 and to the chairman of the board SEK 400,000. Renumeration to the auditors shall be paid in accordance with approved invoices.

Election of board members and auditor
Lars Holmqvist, Maria Holmlund, Ulf Jungnelius, Anders Rylander, Jesper Söderqvist and Henrik Osvald were re-elected as board members for the period until the end of the next AGM, and Marie-Louise Fjällskog and Annika Carlsson Berg were newly elected. Lars Holmqvist was re-elected as the chairman of the board.

The audit firm Grant Thornton Sweden AB was re-elected as auditor for the period until the end of the next AGM, with Stéphanie Ljungberg as the principal auditor.

Decision on guidelines for remuneration to senior executives
The AGM resolved on guidelines for remuneration to senior executives, which means, among other things, that variable cash remuneration shall not exceed 40 percent of the fixed salary.

Authorisation to issue new shares
The AGM resolved to authorise the board of directors to, on one or several occasions, during the period up until the next AGM, decide on a new issue of shares, convertibles and warrants, with or without deviation from the shareholders' preferential rights corresponding to a maximum of 20 percent of the total share capital.

Decision on the issue of warrants to employees and the board of directors
The AGM resolved on a warrant program for employees of 220,000 options whose maximum dilution effect is estimated to amount to a maximum of approximately 0.93 percent of the total number of shares.

The AGM resolved on a warrant program for the board of directors of 200,000 options whose maximum dilution effect is estimated to amount to a maximum of approximately 0.85 percent of the total number of shares.

>4,500

Numbers of patients in studies

28

Publications

19

Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program

No